XML 89 R70.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014
Revenue |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue | $ 2,813 |  |  |  | $ 3,749 |  |  |  | $ 2,813 | $ 3,749 |  |
Revenue. | $ 3,456 | $ 3,924 | $ 3,829 | $ 1,534 | $ 1,874 | $ 2,220 | $ 1,389 | $ 1,303 | 12,743 | 6,786 | $ 5,480 |
Rockefeller |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  |  |  |
Revenue. |  |  |  |  |  |  |  |  | 2,200 | 2,700 | 3,400 |
Bristol-Myers Squibb Company |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  |  |  |
Estimated performance period (in years) |  |  |  |  |  |  |  |  |  |  |  | 5 years
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  | $ 5,000
Reimbursement of external costs (as percent) |  |  |  |  |  |  |  |  |  |  |  | 50.00%
Revenue. |  |  |  |  |  |  |  |  | 2,800 | $ 2,100 | $ 1,300 |
International AIDS Vaccine Initiative |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  |  |  |
Revenue. |  |  |  |  |  |  |  |  | 4,900 |  |  |
Frontier Biotechnologies Inc |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  |  |  |
Revenue. |  |  |  |  |  |  |  |  | $ 1,700 |  |  |

X
- Definition Represents the term of the collaborative arrangement. + References No definition available. + Details
Name: | cldx_CollaborativeArrangementAgreementTerm
Namespace Prefix: | cldx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents percentage of reimbursement of external costs incurred by the company. + References No definition available. + Details
Name: | cldx_ReimbursementOfExternalCostsIncurredPercentage
Namespace Prefix: | cldx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=cldx_RockefellerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=cldx_BristolMeyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=cldx_InternationalAidsVaccineInitiativeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=cldx_FrontierBiotechnologiesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |